GOODWILL AND OTHER INTANGIBLE ASSETS, NET

9 Months Ended

Mar. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS, NET

Goodwill

Goodwill as of March 31, 2018 and June 30, 2017 is presented below:



	Luxury			Consumer Beauty			Professional Beauty			Total
Gross balance at June 30, 2017	$	3,496.8		$	4,732.0		$	967.5		$	9,196.3
Accumulated impairments	(403.7		)	(237.1		)	—			(640.8		)
Net balance at June 30, 2017	$	3,093.1		$	4,494.9		$	967.5		$	8,555.5

Changes during the period ended March 31, 2018:
Acquisitions ^(a)	68.2			—			2.6			70.8
Measurement period adjustments ^(b)	(196.8		)	228.8			(17.2		)	14.8
Foreign currency translation	102.6			179.3			49.8			331.7

Gross balance at March 31, 2018	$	3,470.8		$	5,140.1		$	1,002.7		$	9,613.6
Accumulated impairments	(403.7		)	(237.1		)	—			(640.8		)
Net balance at March 31, 2018	$	3,067.1		$	4,903.0		$	1,002.7		$	8,972.8

^(a)Includes goodwill resulting from the Burberry Beauty Business acquisition (Refer to Note 4—Business Combinations).

^(b)Includes measurement period adjustments in connection with the P&G Beauty Business, ghd, Younique and Burberry Beauty Business acquisitions (Refer to Note 4—Business Combinations).

Other Intangible Assets, net

Other intangible assets, net as of March 31, 2018 and June 30, 2017 are presented below:



	March 31, 2018		June 30, 2017
Indefinite-lived other intangible assets	$	3,241.6	$	3,186.9
Finite-lived other intangible assets, net	5,420.5		5,238.3
Total Other intangible assets, net	$	8,662.1	$	8,425.2

The changes in the carrying amount of indefinite-lived other intangible assets are presented below:



	Luxury			Consumer Beauty			Professional Beauty			Total
Gross balance at June 30, 2017	$	409.8		$	1,696.4		$	1,278.5		$	3,384.7
Accumulated impairments	(118.8		)	(75.9		)	(3.1		)	(197.8		)
Net balance at June 30, 2017	291.0			1,620.5			1,275.4			3,186.9

Changes during the period ended March 31, 2018:
Measurement period adjustments ^(a)	—			—			(14.8		)	(14.8		)
Foreign currency translation	21.5			27.4			20.6			69.5

Gross balance at March 31, 2018	431.3			1,723.8			1,284.3			3,439.4
Accumulated impairments	(118.8		)	(75.9		)	(3.1		)	(197.8		)
Net balance at March 31, 2018	$	312.5		$	1,647.9		$	1,281.2		$	3,241.6

^(a)Includes measurement period adjustments in connection with the ghd acquisition (Refer to Note 4—Business Combinations).

Intangible assets subject to amortization are presented below:



	Cost		Accumulated Amortization			Accumulated Impairment			Net
June 30, 2017
License agreements	$	3,148.4	$	(653.3	)	$	—		$	2,495.1
Customer relationships	1,937.3		(375.0		)	(5.5		)	1,556.8
Trademarks	1,001.1		(141.0		)	—			860.1
Product formulations	389.3		(63.0		)	—			326.3
Total	$	6,476.1	$	(1,232.3	)	$	(5.5	)	$	5,238.3
March 31, 2018
License agreements ^(a)(b)	$	3,542.1	$	(771.5	)	$	—		$	2,770.6
Customer relationships ^(a)(b)	2,022.3		(487.0		)	(5.5		)	1,529.8
Trademarks	1,006.8		(176.6		)	—			830.2
Product formulations and technology ^(a)	380.6		(90.7		)	—			289.9
Total	$	6,951.8	$	(1,525.8	)	$	(5.5	)	$	5,420.5

^(a)Includes measurement period adjustments in connection with the P&G Beauty Business and ghd acquisitions during the nine months ended March 31, 2018 (Refer to Note 4—Business Combinations).

^(b)Includes License agreement of $171.1 and Customer relationships of $6.7 resulting from the Burberry Beauty Business acquisition during the nine months ended March 31, 2018, inclusive of measurement period adjustments (Refer to Note 4—Business Combinations).

Amortization expense was $92.8 and $102.6 for the three months ended March 31, 2018 and 2017, respectively, and $260.6 and $219.0 for the nine months ended March 31, 2018 and 2017, respectively.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details